Lavipharm S.A. (ATH:LAVI)
Greece flag Greece · Delayed Price · Currency is EUR
0.9580
+0.0130 (1.38%)
At close: Dec 23, 2025

Lavipharm Statistics

Total Valuation

Lavipharm has a market cap or net worth of EUR 161.61 million. The enterprise value is 189.24 million.

Market Cap161.61M
Enterprise Value 189.24M

Important Dates

The next estimated earnings date is Thursday, March 26, 2026.

Earnings Date Mar 26, 2026
Ex-Dividend Date Jul 17, 2025

Share Statistics

Lavipharm has 168.69 million shares outstanding.

Current Share Class 168.69M
Shares Outstanding 168.69M
Shares Change (YoY) n/a
Shares Change (QoQ) -0.21%
Owned by Insiders (%) n/a
Owned by Institutions (%) 3.39%
Float n/a

Valuation Ratios

The trailing PE ratio is 78.42.

PE Ratio 78.42
Forward PE n/a
PS Ratio 2.93
PB Ratio 2.88
P/TBV Ratio 12.84
P/FCF Ratio n/a
P/OCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings 57.84
EV / Sales 3.43
EV / EBITDA 18.87
EV / EBIT 37.69
EV / FCF n/a

Financial Position

Current Ratio n/a
Quick Ratio n/a
Debt / Equity 0.60
Debt / EBITDA 3.37
Debt / FCF n/a
Interest Coverage 2.50

Financial Efficiency

Return on Equity (ROE) n/a
Return on Assets (ROA) n/a
Return on Invested Capital (ROIC) n/a
Return on Capital Employed (ROCE) n/a
Revenue Per Employee 195,411
Profits Per Employee 11,603
Employee Count299
Asset Turnover n/a
Inventory Turnover n/a

Taxes

In the past 12 months, Lavipharm has paid 1.32 million in taxes.

Income Tax 1.32M
Effective Tax Rate 39.01%

Stock Price Statistics

The stock price has increased by +29.99% in the last 52 weeks. The beta is 0.63, so Lavipharm's price volatility has been lower than the market average.

Beta (5Y) 0.63
52-Week Price Change +29.99%
50-Day Moving Average 0.83
200-Day Moving Average 0.81
Relative Strength Index (RSI) 79.65
Average Volume (20 Days) 187,113

Short Selling Information

Short Interest n/a
Short Previous Month n/a
Short % of Shares Out n/a
Short % of Float n/a
Short Ratio (days to cover) n/a

Income Statement

In the last 12 months, Lavipharm had revenue of EUR 55.11 million and earned 3.27 million in profits. Earnings per share was 0.02.

Revenue55.11M
Gross Profit 24.37M
Operating Income 5.02M
Pretax Income 3.38M
Net Income 3.27M
EBITDA 9.28M
EBIT 5.02M
Earnings Per Share (EPS) 0.02
Full Income Statement

Balance Sheet

The company has 6.17 million in cash and 33.81 million in debt, giving a net cash position of -27.64 million or -0.16 per share.

Cash & Cash Equivalents 6.17M
Total Debt 33.81M
Net Cash -27.64M
Net Cash Per Share -0.16
Equity (Book Value) 56.08M
Book Value Per Share 0.33
Working Capital n/a
Full Balance Sheet

Cash Flow

Operating Cash Flow n/a
Capital Expenditures n/a
Free Cash Flow n/a
FCF Per Share n/a
Full Cash Flow Statement

Margins

Gross margin is 44.22%, with operating and profit margins of 9.11% and 5.94%.

Gross Margin 44.22%
Operating Margin 9.11%
Pretax Margin 6.14%
Profit Margin 5.94%
EBITDA Margin 16.84%
EBIT Margin 9.11%
FCF Margin n/a

Dividends & Yields

This stock pays an annual dividend of 0.02, which amounts to a dividend yield of 2.09%.

Dividend Per Share 0.02
Dividend Yield 2.09%
Dividend Growth (YoY) n/a
Years of Dividend Growth 1
Payout Ratio n/a
Buyback Yield n/a
Shareholder Yield 2.09%
Earnings Yield 2.02%
FCF Yield n/a
Dividend Details

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

The last stock split was on August 1, 2022. It was a reverse split with a ratio of 0.3333333333.

Last Split Date Aug 1, 2022
Split Type Reverse
Split Ratio 0.3333333333

Scores

Altman Z-Score n/a
Piotroski F-Score 1